Strive Health Secures $550M Series D; FDA to Review Generative AI Mental Health Devices

1. Drug Research and Development

• Ridge Biotechnologies

Financing Amount:$25 million

Round: Seed Round

Ridge Biotechnologies is an AI-driven biotechnology company based in the United States, focusing onPrecision Enzyme Design and Targeted Drug DevelopmentThe company relies on an artificial intelligence platform to address the low efficiency of traditional enzyme engineering and new drug target identification, thereby accelerating the drug discovery and development process. The funds from this round will mainly be used to expand the R&D team, optimize the AI-driven molecular design platform, and push core target projects into the early experimental stage.

• Valo Health

Funding Amount: Undisclosed (Research grant received)

Round/Type: Research Grant (Grant) Cooperation/Funding

Valo Health is a pharmaceutical/drug discovery platform company that utilizes human biological data and AI. Its core competencies lie inIntegration of Large-Scale Real-World Data, Genomics/Multi-Omics, and Network Biology Analysis, as well as artificial synthetic chemistry, toDiscovery of New Druggable Targets, and accelerate the phase from target validation to candidate drug molecules. Valo was awarded a research grant (Targets to Therapies Initiative) by the Michael J. Fox Foundation to explore the mechanism of action of NOD2, a target associated with Parkinson's disease, using genetics, multi-omics, and network biology analysis to clarify the association between NOD2 and Parkinson's disease as well as immune diseases, thereby providing evidence for its feasibility as a drug target.

2. Medical Services and Nursing Management

• Strive Health

Financing Amount:$550 million

Round:Series D

Strive Health was founded in the United States and focuses onValue-based Healthcare Platform for Kidney CareStrive Health, LLC is dedicated to improving the diagnosis and treatment experience for patients with chronic kidney disease and renal failure through data-driven and AI technologies. By collaborating with healthcare providers and payers, the company reduces the costs of dialysis and hospitalization while enhancing patients' quality of life. The funds from this round will be used to expand market coverage, deepen cooperation with healthcare systems, and promote a new generation of AI-driven kidney health management tools.

• Teton.ai

Financing Amount:$20 million

Round: Growth Financing

Teton.ai is a Danish health technology company dedicated toRevitalizing Elderly Care through AI and Sensing TechnologiesThe company provides real-time data support for nursing homes and home care by deploying intelligent monitoring and assistance systems, thereby reducing the burden on caregivers and improving the health management of the elderly. The funds will be used to expand the layout in the European market, promote product commercialization, and continue optimizing the application of AI models in clinical care.

3. Digital Health and Assistive Tools

• LightSpun

Financing Amount:$13 million

Round:Series A

LightSpun is headquartered in the United States.Focus on Using AI Technology to Reconstruct Dental Insurance ManagementThe platform developed by the company can automate, make transparent, and enhance the efficiency of dental insurance claims processes, reducing friction among patients, insurance companies, and dental clinics. The funds from this round will be used for the iterative development of the technology platform, expanding cooperation with insurance companies, and promoting further penetration in the U.S. market.

• Intrepid Phoenix Ventures

Financing / Funding Amount: Undisclosed Specific Amount (ReceivedSBIR Phase I Grant)

Round/Type: Government-funded Cooperation/Research Cooperation (SBIR Phase I grant）

Intrepid Phoenix Ventures is a technology/software company focused onSubstance Abuse Disorder Recovery Support Software Platform.Through AI-driven applications, provide personalized support, progress monitoring, and intervention functions for treatment providers and patients to help ensure continuity and effectiveness during the patient's rehabilitation process.CompanyIn collaboration with the Indiana University School of Social Work, received funding from the U.S. Department of DefenseSBIR Phase I Grant for the Development of Software/Intervention Tools Related to Social Work/Rehabilitation Support.

• Meela

Financing Amount: Undisclosed

Round: Undisclosed

Meela is a company focused onAI Mental Health Solutions, introduced a personalized AI companion app,Mainly targeting the elderly population, aiming to alleviate the loneliness epidemic. The app provides companionship and psychological support to users through natural language interaction and emotion recognition technology. The expected funds will be used for product promotion, technology upgrades, and cooperation with medical and elderly care institutions.

【FDA to Meet in November to Review Risk and Regulatory Pathways for Generative AI-Supported Digital Mental Health Devices

On September 11, 2025, the U.S. Food and Drug Administration (FDA) announced that its Digital Health Advisory Committee (DHAC) willNovember 6, 2025Hold a public meeting specifically to evaluate"Generative Artificial Intelligence-Enabled Digital Mental Health Medical Devices". These devices include emerging tools such as chatbots and virtual therapists. The conference agenda will explore the benefits of these devices (e.g., scalability, convenient and timely intervention) and risks (output uncertainty, misleading information, privacy and security issues, etc.), as well as examine the regulatory requirements these products should meet in terms of premarket evidence and postmarket monitoring. The FDA has opened a public docket for public comments, and background materials will also be disclosed at least two business days before the meeting.

【Tempus Pixel-AI Update Receives FDA 510(k) Clearance: New Cardiac MRI Functionality Launched

On September 11, 2025, Tempus AI announced its enhanced cardiac imaging platform.Tempus PixelObtained in the United StatesFDA 510(k) Special Clearance. This update enables the software to directly generate T1 and T2 inline maps from original cardiac MRI data, providing quantitative numerical images of myocardial tissue characteristics such as fibrosis, inflammation, and edema. This functionality can be utilized even when the MRI scanner itself lacks native mapping capabilities, enhancing the ability and sensitivity of clinical assessments of cardiac tissue conditions. The update is expected to improve the efficiency and diagnostic accuracy of medical imaging, offering radiologists and cardiologists more comprehensive and personalized imaging information.

【Health AI 2025 Conference Held in Washington, Focuses on Policy/Regulation/Ethical Issues in Medical AI

On September 10, 2025, an event namedHealth AI 2025An invitation-only conference, hosted by the Consumer Technology Association (Hosted by the Consumer Technology Association (CTA). Meeting participants include government regulators, technology company representatives, hospital systems, health insurance and healthcare service providers, academics, and others. The theme focuses on the use of AI in healthcare, particularly its clinical applications, regulatory requirements, policy frameworks, and ethical issues affecting the deployment and adoption of health technology. Discussions addressed how to establish standards and governance structures for medical AI in terms of regulation and policy, as well as how to balance challenges such as innovation with patient safety, privacy, and equity.

[California Legislature PassesSB 53 Bill: Frontier AI Model Transparency and Safety Accountability Legislation to Be Submitted to the Governor

September 2025On the 13th, the California legislature passed a bill namedSB 53（Transparency in Frontier Artificial Intelligence Act, TFAIA）The bill, which aims to target large"Frontier AI" models/developers are subject to stricter transparency and safety accountability requirements. The main contents of the bill include: requiring these large AI labs/companies to disclose their safety and security protocols as well as risk evaluation mechanisms, while allowing some content to be withheld in order to protect commercially sensitive and national security information; mandating that critical safety incidents (e.g., model失控, cyberattacks, or the use of models for biological/chemical/radiological/nuclear weapons threats) must be reported to the state attorney general within 15 days; providing whistleblower protections; and establishing public cloud computing resources ("CalCompute") to lower the barrier for startups and academia to engage in cutting-edge model research and development. The bill has now been sent to California Governor Gavin Newsom for signing or vetoing.